Editorial: Advancements in HPV research: integrating diagnostics, vaccination, and women’s health

Abstract

Human papillomavirus (HPV) infection leading to cervical cancer remains one of the most urgent public health challenges worldwide. In 2022 alone, there were an estimated 662,301 new cervical cancer cases and 348,874 deaths globally, with the burden heavily affecting low-and middleincome countries (LMICs) where access to prevention, screening, and treatment remains limited (1,2). Persistent infection with high-risk HPV genotypes, especially types 16 and 18, underpins nearly all cases of cervical cancer, causing over 300,000 deaths each year (3). Despite significant scientific advances in HPV diagnostics and vaccine development over the past two decades, translating these innovations into equitable healthcare practices remains a major global challenge (4). A clearer understanding of how best to deliver evidence-based interventions in real-world settings is crucial to bridging the gap between research and actual health outcomes, especially in low-resource settings where vaccination uptake, screening coverage, sociocultural barriers, and health system limitations continue to pose challenges. HPV vaccination has proven highly effective in reducing cervical disease, yet uptake varies considerably, often reflecting underlying social and structural factors.vaccine uptake among women in Africa. Their analysis identifies persistent inequalities driven by misinformation, inadequate health education, limited health system capacity, and structural barriers such as distance and cost. The review emphasises that improving vaccination coverage requires multipronged approaches, policy alignment, community-based interventions, and targeted communication strategies.The social dimension of vaccination is further examined by Matsangaise et al., who analysed vaccine sentiment on South African social media prior to the COVID-19 pandemic. Their study reveals widespread mistrust and misinformation, highlighting that digital platforms play a significant role in shaping public perceptions of vaccination. These findings reflect global concerns about the profound and often overlooked impact of online discourse on vaccine confidence. These findings have significant implications for resource-limited settings, where cost and logistical barriers can hinder the completion of multi-dose regimens.Individually and collectively, the contributions in this research topic emphasise that scientific advances alone are insufficient to attain equitable HPV prevention. Effective integration demands attention to three overarching imperatives:Health systems should prioritise integrated models that bring screening, vaccination, and followup care into the same continuum to improve uptake and retention.As demonstrated by Matsangaise et al., communication challenges can undermine even the most robust scientific tools. Enhancing health literacy and combating misinformation must remain core components of national immunisation strategies.There is no single universal approach. Implementation must consider context-specific barriers, resource availability, and cultural norms to achieve meaningful and sustainable progress.While progress is evident, significant gaps persist, especially in strategies for engaging underserved populations, maintaining long-term vaccine confidence, and translating scientific evidence into national policy.The collective findings of these studies highlight that integrating diagnostics, vaccination, and women's health through an implementation science lens is essential to accelerating regional and global efforts to eliminate HPV. By placing implementation strategies, vaccine uptake, communication dynamics, and immunogenicity within broader health system and societal contexts, this collection enhances both scientific understanding and practical measures.Continued interdisciplinary collaboration will be key to ensuring that innovations lead to equitable and measurable reductions in HPV-related disease burden.